20th Biosimilar Medicines Conference insights
🌟 Insights from Day 2 of last week’s Biosimilar Medicines Conference in Amsterdam! Last Friday’s sessions highlighted key updates from global regulators, including the FDA, European Medicines Agency, ANVISA in Brazil and the Medicines and Healthcare products Regulatory Agency. Discussions have shifted away from the need for confirmatory efficacy studies to focus on comprehensive physicochemical […]
20th Biosimilar Medicines Conference in Amsterdam
We’re excited to announce that Dr. Ronald Koning, our Chief Strategic Advisor, will be at the upcoming Biosimilar Medicines Conference.Join us in Amsterdam on 18-19 April to explore how Biokinetica’s expertise in biosimilar clinical trials can support your projects and contribute to your success. Let’s drive the future of biosimilars together!
CEBioForum 2024
We’re excited to announce that our COO, Agnieszka Kulesza, will be a panelist at the upcoming CEBioForum2024 sharing her expertise on developing a winning clinical trial strategy. ➡️ We look forward to the event and the opportunity to learn from other industry leaders in the CEE region. Stay tuned for key takeaways and insights! CEBioForum […]
AQVIA: 110 biological medicines are set to lose patent protection
According to IQVIA, 110 biological medicines in Europe are set to lose patent protection by 2032. This has further strengthened Biokinetica’s interest in supporting biosimilar development. We are proud to support bringing more affordable treatments but also aligns with sustainable and cost-effective strategies in the evolving pharmaceutical landscape.
FS: A breakthrough in cancer treatment emerges
This week in FridayScience: A breakthrough in cancer treatment emerges – ONCOTECH. This novel therapy approach merges oncolytic virotherapy and adoptive TCell therapy, synergizing their strengths against cancerous tumors. By attaching oncolytic viruses to T cells and targeting the PD-L1 gene, ONCOTECH promotes oncolysis, while T cells trigger cytotoxic effects, enhancing antitumor immunity and reducing […]
New Year’s Meeting of the Polish-Swiss Chamber of Commerce
Thrilled to express our gratitude for the invitation to the distinguished New Year’s Meeting hosted by the Polish-Swiss Chamber of Commerce. It was a fantastic opportunity to connect with professionals from Swiss companies or, like Biokinetica, those working with Swiss Clients. Special thanks to Sandoz Polska for their hospitality and the chance to tour their […]
Chillizet radio station interview [podcast]
Biokinetica believes in the crucial role volunteers and patients play in advancing medical science, which is why we aim to build trust and foster a positive perception of early-phase clinical trials. Therefore, Biokinetica carries out its educational mission, and as part of this, our medical specialists, Dr. Joanna Kołodziej and Dr. Aleksander Kiecana, participated in an interview […]
Clinical trials that will shape medicine in 2024
In today’s FridayScience we’re looking into the future: Nature Portfolio has published a list of clinical trials believed to shape medicine in 2024. Among them, we see base editing for hypercholesterolemia, immunotherapy for melanoma, antibody–drug conjugate (ADC) for metastasis or a T cell vaccine for HIV. The inclusion of AI and personalized medicine in ClinicalTrials […]
